- Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade
-
Yim HJ, Hwang SG
- KMID: 1705199
- Clin Mol Hepatol.
- 2013 Sep;19(3):195-209.
- doi: 10.3350/cmh.2013.19.3.195
Although much advancement has been achieved in the treatment of chronic hepatitis B, antiviral resistance is still a challenging issue. Previous generation antiviral agents have already developed resistance in a... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
-
Park CH, Jung SW, Shin JW, Bae MA, Lee YI, Park YT, Chung HS, Park NH
- KMID: 2363033
- Clin Mol Hepatol.
- 2016 Mar;22(1):152-159.
- doi: 10.3350/cmh.2016.22.1.152
BACKGROUND/AIMS: Tenofovir disoproxil fumarate (TDF) exhibits similar antiviral efficacy against treatment-naïve and lamivudine (LAM)-resistant chronic hepatitis B (CHB). However, there are few clinical reports on the antiviral effects of TDF-LAM... -
- CITED
-
- Close
- SHARE
-
- Close
- The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients
-
Jung HJ, Kim YS, Kim SG, Lee YN, Jeong SW, Jang JY, Lee SH, Kim HS, Kim BS
- KMID: 1737597
- Clin Mol Hepatol.
- 2014 Mar;20(1):38-46.
- doi: 10.3350/cmh.2014.20.1.38
BACKGROUND/AIMS: Lipid profile and insulin resistance (IR) are associated with hepatitis C virus (HCV) and may predict the chronic hepatitis C (CHC) treatment response. The aim of this study was... -
- CITED
-
- Close
- SHARE
-
- Close
- A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
-
You BC, Kim YS, Kim HI, Kim SH, Park SS, Seo YR, Kim SG, Lee SW, Kim HS, Jeong SW, Jang JY, Kim BS
- KMID: 1392906
- Clin Mol Hepatol.
- 2012 Sep;18(3):272-278.
- doi: 10.3350/cmh.2012.18.3.272
BACKGROUND/AIMS: When combined with pegylated interferon alpha-2b (Peg-IFN alpha-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Outcomes of Lamivudine Therapy in HBeAg Positive Chronic Hepatitis B with Minimally Elevated ALT
-
Han DH, Park NH, Shin JW, Jung SW, Hwang YT, Kim HS, Jeong ID, Bang SJ, Kim DH
- KMID: 760718
- Korean J Hepatol.
- 2007 Jun;13(2):146-156.
BACKGROUND/AIMS: The aim of this study was to compare the efficacy of lamivudine therapy between chronic hepatitis B (CHB) patients, whose ALT levels less than 2 times the upper... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Tenofovir-based Rescue Therapy for Patients with Drug-resistant Chronic Hepatitis B
-
Choi K, Lee HM, Jun BG, Lee SH, Kim HS, Kim SG, Kim YS, Kim BS, Jeong SW, Jang JY, Kim YD, Cheon GJ
- KMID: 2373178
- Korean J Gastroenterol.
- 2015 Jan;65(1):35-42.
- doi: 10.4166/kjg.2015.65.1.35
BACKGROUND/AIMS: Tenofovir disoproxil fumarate (TDF) plays a pivotal role in the management of drug-resistant chronic hepatitis B. However, it remains unclear whether TDF-nucleoside analogue combination therapy provides better outcomes than... -
- CITED
-
- Close
- SHARE
-
- Close
